AGP Executive Report
Last update: 8 hours agoBoardroom in Health Tech: GSK appoints Roy Jakobs (CEO of Royal Philips, Amsterdam) as a Non-Executive Director from 13 July 2026, adding deep experience in patient monitoring, imaging and intervention to its push for faster growth and better medicines. Weight & Brain Tumours: A new clinical trial reports setmelanotide (for hypothalamic obesity after brain tumours) can improve BMI and health outcomes, offering hope for patients in the Netherlands facing long-term hormone and metabolism damage. Heat Preparedness: WHO warns Europe—including the Netherlands—must prepare for more extreme heatwaves, citing that fewer than half of countries have national heat-health action plans, and urging early warnings and targeted support for vulnerable groups. Gut Health Innovation: Dutch Nizo Food Research teams up with Winclove Probiotics to speed up discovery and development of novel probiotic solutions, aiming to turn microbiome science into evidence-based products. Kidney Disease Research: ORBCEL-M stem cell therapy shows promise in the NEPHRSTROM trial, with a single dose linked to better-preserved kidney function and plans for larger studies. Public Health & Safety: Dutch prosecutors begin criminal action over Tata Steel’s harmful emissions, as regulators and health advocates push for accountability.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![[Latest] Global Microfluidic Devices Market Size/Share Worth USD 182.98 Billion by 2035 at a 22.36% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)](https://ml.globenewswire.com/Resource/Download/585d2565-8ffa-4130-85e9-fe3810811108/north-america-microfluidic-devices-market-size-2025-to-2035-usd-billion-.webp)
